About the Author

Andy Wilcox is an independent researcher writing about viruses, pandemics, and public-health response. He is not a physician, and nothing here is medical advice — his work is the product of disciplined primary-source research, applying the same analytical approach he has used across 30+ years as a consultant, operating executive, and investor.

He holds an MBA from Duke University's Fuqua School of Business and is a licensed CPA and certified Project Management Professional (PMP) — a background built on evaluating evidence carefully and reasoning with data. His consulting career began at Ernst & Young, where he led business-process and systems-implementation projects for Fortune 500 clients including the pharmaceutical company Eli Lilly and the hospital network Partners HealthCare, giving him early exposure to how large healthcare and life-sciences organizations operate.

Since 2015 he has served on the Executive, Screening, and Due Diligence committees of Triangle Angel Partners, an angel fund that invests in life-sciences and high-tech companies alongside members who include physicians, PhDs, and career investors — its portfolio includes medical-technology ventures such as Deep Blue Medical and OrbitalRX. Evaluating early-stage companies means reading the underlying science critically, pressure-testing claims, and separating evidence from hype — the same habits he brings to this research. He is comfortable with data and probability, having built Monte Carlo forecasting models and led complex quantitative analysis, which shapes how he reads epidemiological data and study results rather than headlines.

His focus on viruses began during the COVID-19 pandemic, and it began personally. His aging parents were confined to their assisted-living facility, and watching the toll of that isolation led him to research its emotional impact on at-risk populations — which widened into a broader study of what triggers a pandemic, which public-health responses hold up under scrutiny, and how outbreaks ripple through economies and communities. Since 2020 he has read and summarized hundreds of articles and peer-reviewed studies and tracked every major variant wave, citing primary sources rather than aggregating other websites.

CoronavirusQuestions.com is where that work began. It's part of Virus Questions (virusquestions.com), a network of independent virus-information resources he founded that also includes HantavirusQuestions.com, EbolaQuestions.com, and NorovirusQuestions.com. You can find him on LinkedIn at linkedin.com/in/andyswilcox.

• Coronavirus Origin — the zoonotic spillover and lab-leak hypotheses
• COVID-19 History & Timeline — from December 2019 to today
• Variants — Alpha through the Omicron subvariants
• Vaccines — mRNA technology, efficacy, and approval history
• Symptoms — how COVID-19 presents across variants
• Treatment — antivirals, hospital care, and home management
• Long COVID — post-acute sequelae and ongoing research
• Global Impact — mortality, economic, and societal effects
• Misinformation — debunked claims with primary-source citations
• Anti-Vaccine Movement — common arguments and the evidence against them
• Research — ongoing and landmark studies

Every factual claim about science or medicine on this site is supported by primary sources — the CDC, WHO, NIH, and peer-reviewed literature. Where scientific or public-health consensus exists, content reflects it. Where evidence is contested or preliminary, that uncertainty is stated explicitly.

In practice, on COVID-19 specifically, that means four habits:

• Name the study behind the agency's figure. CDC's symptoms page lists symptoms without frequencies, so this site does not invent them; it cites the WHO-China Joint Mission's 55,924 lab-confirmed cases for the original strain and the ZOE matched-cohort analysis for Delta and Omicron, with odds ratios and confidence intervals attached.
• Read the dataset, not just the dashboard. The conclusion that no SARS-CoV-2 lineage can currently be called dominant in the United States comes from CDC's own variant-proportions file, where every national estimate in the most recent period carries CDC's low-precision flag. The inference is ours and is shown so it can be checked.
• Date every figure whose measurement has stopped. The familiar "1 in 20 US adults has Long COVID" is real, and it is from a survey round that closed on September 16, 2024. Quoting it undated in 2026 would present history as news.
• Refuse the numbers that cannot be computed honestly. This site publishes no current US case-fatality rate or population hospitalisation rate for COVID-19, because there is no denominator for one. Those cells are blank, with the reason, on the risk perspective page.

Where the author's background is directly relevant — the economic and financial analysis behind the economic impact page — it is stated there and nowhere else. It is not relevant to clinical content and is never presented as clinical authority.

For a full description of sourcing standards and correction policy, see the How We Research page. Errors found and fixed are recorded on the corrections page, including what was published, what it says now, and the source that settled it.